Search

Displaying results 3701 - 3710 of 8974 in total
  1. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite. … Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria.

    Synonyms: Lumefantrine co-artemether
  2. Drug

    Clofibrate

    go.drugbank.com/drugs/DB00636
    ApprovedWithdrawn

    A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

  3. Drug

    Camostat

    go.drugbank.com/drugs/DB13729
    Investigational

    [A198807] Camostat mesylate inhibits cholecystokinin, pro-inflammatory cytokines, and serine proteases, leading to it being investigated for multiple indications including the treatment of COVID-19. … Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.

  4. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Lorazepam

    go.drugbank.com/drugs/DB00186
    ApprovedInvestigational

    [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. … The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]

    Synonyms: o-Chloroxazepam, o-Chlorooxazepam
  6. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases. … Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.

  7. Drug

    Lobeglitazone

    go.drugbank.com/drugs/DB09198
    Investigational

    Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes. … By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and

  8. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients

  9. Drug

    Pefloxacin

    go.drugbank.com/drugs/DB00487
    Approved

    A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  10. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.